This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanchez-Cespedes, M. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Sanchez-Cespedes, M. Articles by Sidransky, D.

Gene Promoter Hypermethylation in Tumors and Serum of Head and Neck Cancer Patients¹

Department of Otolaryngology–Head and Neck Surgery, Division of Head and Neck Cancer Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21206-2198 [M. S-C., L. W., W. K., J. J., D. S.]; The Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 [M. E., J. G. H.]; and Department of Otolaryngology-Head and Neck Surgery, Wayne State University, Detroit, Michigan 48201 [G. H. Y., H. N-D.]

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Promoter hypermethylation is an important pathway for repression of gene transcription in cancer cells. We analyzed aberrant DNA methylation at four genes in primary tumors from 95 head and neck cancer patients and then used the presence of this methylation as a marker for cancer cell detection in serum DNA. These four genes were tested by methylation-specific PCR and included: p16 (CDKN2A), O⁶-methylguanine-DNA-methyltransferase, glutathione S-transferase P1, and death-associated protein kinase (DAP-kinase). Fifty-five % (52 of 95) of the primary tumors displayed promoter hypermethylation in at least one of the genes studied: 27% (26/95) at p16, 33% (31 of 95) at O⁶-methylguanine-DNA-methyltransferase; and 18% (17 of 92) at DAP-kinase. No promoter hypermethylation was observed at the glutathione S-transferase P1 gene promoter. We detected a statistically significant correlation between the presence of DAP-kinase gene promoter hypermethylation and lymph node involvement (P = 0.014) and advanced disease stage (P = 0.016). In 50 patients with paired serum available for epigenetic analysis, the same methylation pattern was detected in the corresponding serum DNA of 21 (42%) cases. Among the patients with methylated serum DNA, 5 developed distant metastasis compared with the occurrence of metastasis in only 1 patient negative for serum promoter hypermethylation (P = 0.056). Promoter hypermethylation of key genes in critical pathways is common in head and neck cancer and represents a promising serum marker for monitoring affected patients.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
HNSCC⁴ cancer remains a morbid and often fatal disease. The overall survival has not changed in recent years, despite extensive research on the biological and molecular features of HNSCC. Among the more pressing problems in clinical management are the lack of early detection and the high incidence of local-regional recurrence, even with aggressive surgical therapy (1) . Therefore, it is important to develop new molecular targets to be used as diagnostic and prognostic indicators.

An important mechanism for gene transcriptional inactivation is hypermethylation at the CpG islands within the promoter regions (2) . Some tumor suppressor genes such as p16, VHL, and MLH1 have been found to harbor promoter hypermethylation associated with loss of protein expression in cancer cells (3, 4, 5) . Several tumor types have also shown aberrant methylation at CpG islands in other genes, including the detoxifying gene GSTP1 (6) , the DNA repair gene MGMT (7) , and the potential metastasis inhibitor gene DAP-kinase first occurrence. (8) . The presence of epigenetic methylation might also be useful as a molecular target for tumor cell detection.

The presence of abnormally high DNA concentrations in the serum of patients with neoplasms of various types was described decades ago (9) . Recent publications have demonstrated the tumor origin of this DNA in cancer patients by confirming the presence of tumor-specific molecular abnormalities in the serum. K-ras or p53 mutations have been detected in the serum of colorectal (10 , 11) , pancreas (12) , and breast (13) cancer cases and N-ras mutations in some hematological diseases (14) . Other DNA abnormalities, such as loss of heterozygosity) and MI, have also been reported in the serum of head and neck (15) , lung (16 , 17) , renal (18) , and breast (13) cancer patients. Moreover, recent studies have demonstrated the presence of gene promoter hypermethylation in the serum DNA of lung (8) , liver (19) , and breast (13) cancer patients. However, the clinical significance of these observations is still not understood.

In the present study, we have analyzed the promoter hypermethylation pattern of the p16, MGMT, GSTP1, and DAP-kinase genes in the tumor DNA of 95 head and neck primary tumors. The methylation patterns found in the tumors were used as molecular markers for cancer cell detection in the paired serum DNA. Almost half of the HNSCC patients with methylated tumors were found to display these epigenetic changes in the paired serum.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Sample Collection and DNA Extraction.
Ninety-five primary tumors where collected from patients diagnosed with HNSCC between the years 1993 and 1999. Patients were treated at the Johns Hopkins University School of Medicine or at the Wayne State University. Fresh tumors were obtained from surgical resection of the HNSCC patients. Serum samples were collected from the same patients at diagnosis and stored at -80°C. Tumor and serum DNA was prepared as described previously (15) . A single follow-up serum was collected at 6 to 72 months after treatment in nine patients from Johns Hopkins University School of Medicine.

Bisulfite Treatment.
DNA from tumor and serum specimens was subjected to bisulfite treatment, as described previously (20) . Briefly, 1 µg of DNA was denatured by NaOH and modified by sodium bisulfite. DNA samples were then purified using the Wizard purification resin (Promega Corp.), again treated with NaOH, precipitated with ethanol, and resuspended in water.

MSP.
The modified DNA was used as a template for MSP. DNA methylation patterns in gene CpG islands were determined by chemical modification of unmethylated cytosines to uracil and subsequent PCR using primers specific for either methylated or the modified unmethylated sequences (20) . Appropriate negative and positive controls were included in each PCR reaction. Primer sequences for the p16 (20) , MGMT (7) , DAP-kinase (8) , and GSTP1 (21) genes were as described previously: for the p16 gene, unmethylated reaction: 5'-TTATTAGAGGGTGGGGTGGATTGT-3' (sense), 5'-CAACCCCAAACCACAACCATAA-3' (antisense); methylated reaction: 5'-TTATTAGAGGGTGGGGCGGATCGC-3' (sense), 5'-GACCCCGAACCG-CGACCGTAA-3' (antisense); for the MGMT gene, unmethylated reaction: 5'-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3' (sense), 5'-AACTCCACACTCTTCCAAAAACAAAACA-3' (antisense); methylated reaction: 5'-TTTCGACGTTCGTAGGTTTTCGC-3' (sense), 5'-GCACTCTTCCGAAA-ACGAAACG-3' (antisense); for the DAP-kinase gene, unmethylated reaction: 5'-GGAGGATAGTTGGATTGAGTTAATGTT-3' (sense), 5'- CAATCCCT-CCCAAACACCAA-3' (antisense); methylated reaction: 5'-GGATAGTCGGATCGAGTTAACGTC-3' (sense), 5'-CCCTCCCAAACGCCG-3' (antisense); for the GSTP1 gene, unmethylated reaction: 5'-GATGTTTGGGGTGTAGTGGTTGTT-3' (sense), 5'-CCACCCCAATACTAAATCACAACA-3' (antisense); methylated reaction: 5'-TTCGGGGTGTAGCGCTCGTC-3' (sense), 5'-GCCCCAATACTAAATCACGACG-3' (antisense).

Each PCR product (20 µl) was directly loaded onto 6% nondenaturing polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination. Previous studies have demonstrated that this method has a sensitivity of 1:1000 (i.e., can detect one methylated genome in 1000 unmethylated genomes; Ref. 20 ).

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Gene Promoter Hypermethylation Profiles in Primary Head and Neck Tumors.
Aberrant methylation at any of the genes studied was detected in 52 of 95 (55%) primary head and neck tumors. Representative results are shown in Fig. 1A . The p16 tumor suppressor gene demonstrated promoter hypermethylation in 26 of 95 (27%), the MGMT gene in 31 of 95 (33%), and the DAP-kinase gene in 17 of 92 (18%) tumors (Fig. 1B) . No methylation changes were found at the GSTP1 gene in 41 tumors analyzed. Nineteen of the 52 (36%) methylation-positive tumors showed epigenetic changes at more than one of the genes tested, and three of them (3%) were positive for all of the three markers simultaneously. However, each of these hypermethylated loci acted as independent events, and the concordance of all of the genes in these three tumors was at the predicted level for a nonassociated event.

View larger version (54K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. Gene promoter hypermethylation in primary tumors and serum from HNSCC patients. A, representative examples of MSP of p16, MGMT, and DAP-kinase in tumor (T) and serum (S) including water as a negative control (C-) and a positive methylated control (C+). Lanes U and M correspond to the unmethylated and methylated reactions, respectively. B, percentages of patients with epigenetic alterations in the primary tumor and serum. DAP-K, DAP-kinase.

Finally, in seven of the patients showing promoter hypermethylation at the tumor DNA, a second serum specimen extracted several months after surgery (between 6 and 72 months) was available for methylation analysis. None of the four patients negative for gene promoter hypermethylation at the serum DNA showed any aberrant methylation in the DNA from the second serum specimen (collected between at 7 and 72 months). All of them were clinically free of disease. One of the patients positive for DAP-kinase promoter hypermethylation in the tumor and serum DNA was negative in the serum specimen collected 29 months after surgery, when he did not have any evidence of disease. The remaining two patients were positive for aberrant methylation in the serum collected months after surgery (5–6 months). However, the follow-up of these two patients was too short to make definitive conclusions.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Hypermethylation of normally unmethylated CpG islands in the promoter regions often occurs in important tumor suppressor genes such as VHL, hMLH1, and p16 (3, 4, 5) . Recently, loss of expression in other interesting genes has been found in cancer cells through promoter methylation. Some of these genes include the detoxifying gene GSTP1, commonly altered in prostate, breast, and renal cancer (6 , 21) , the DNA repair gene MGMT, frequently inactivated in brain, colorectal, lung, and lymphomas (7) , and the potential metastasis inhibitor DAP-Kinase gene altered in lymphomas, leukemias, and lung cancer (8 , 22) . These epigenetic alterations have been successfully used as indicators of neoplastic serum DNA in lung cancer patients (8) .

Approximately one-quarter of the HNSCC analyzed in this study inactivated the p16 tumor suppressor gene through promoter hypermethylation. These results are in agreement with our previous data (23) and highlight the importance of p16 methylation as a common pathway of p16 gene inactivation in HNSCC. Moreover, the MGMT gene showed aberrant methylation patterns in one-third of the tumors, similar to recent findings in a limited number of head and neck cancers (7) . GSTP1 was not methylated in any of the HNSCC analyzed, supporting others’ results (21) and suggesting a role for this gene in only specific tumor types, such as breast and prostate cancer (6 , 21) . We found for the first time promoter hypermethylation of the DAP-kinase gene in HNSCC. The DAP-kinase protein is a calcium/calmodulin-dependent enzyme that phosphorylates serine/threonine residues. This protein has been classified as a positive mediator of apoptosis induced by IFN-. DAP-kinase expression is frequently lost in highly metastatic murine lung tumors compared with their low metastatic counterparts. In addition, restoration of DAP-kinase protein to physiological levels in highly metastatic Lewis carcinoma cells suppressed their ability to form metastasis (24) . Interestingly, we found a positive correlation between methylation of DAP-kinase and the presence of lymph nodes metastases, supporting a role for this protein in tumor dissemination.

After screening for methylation changes in the primary tumor tissue, we analyzed the paired serum DNA in a subset of the patients. Forty-two % of the tumors with any epigenetic alteration showed the same change in the serum DNA using the MSP assay (sensitivity, 1:1000). We described previously the detection of loss of heterozygosity and MI in 20% of paired serum samples from HNSCC patients (15) . The lower frequency of detection by microsatellite analysis is probably attributable to its lower sensitivity (approximately 1:200 for MI) compared with MSP (20 , 25 , 26) . Differences in assay sensitivity for distinct markers may also account for the observation of promoter hypermethylation at the MGMT but not at the DAP-kinase gene in the serum specimen from two patients. Preliminary studies in serum and bronchoalveolar lavage fluid did not detect aberrant methylation in lung cancer patients that lacked hypermethylation patterns in the primary tumors (8 , 26) . Similarly, we did not detect abnormal promoter hypermethylation in the serum DNA of 25 HNSCC patients in whom the tested markers were not altered in the primary tumor.

The mechanism leading to the presence of free tumor DNA in the serum of cancer patients is not well understood. DNA may simply be released from the tumor tissue from nonviable (apoptotic) neoplastic cells. On the other hand, tumor serum DNA may also originate from cells that have left the primary site and have invaded the circulatory system but are still not capable of metastasis to new organs. After resection of the primary tumor, detection of DNA alterations in the serum may be an indicator of high risk of local or distant recurrence in cancer patients.

The clinical implications of detecting genetic alterations in serum of cancer patients are not clear. It has been reported that DNA concentrations in the serum from cancer patients are higher compared with the normal population, especially in the presence of metastatic disease. Interestingly, it was also observed that DNA levels declined after radiotherapy, especially when the treatment was beneficial. However, there was no correlation between the DNA concentration and several clinical features such as tissue of origin, tumor size, or stage of the disease (9) . In addition, recent publications have reported a lack of association between the presence of genetic alterations in serum and the clinicopathological variables such stage, tumor size, lymph node involvement, or histological stage in renal, colorectal, breast, and non-small cell lung cancer (8 , 11 , 13 , 17) . However, in pancreatic cancer, plasma K-ras mutations have correlated with the development of distant metastasis and shorter survival (27) .

Aberrant methylation in the serum DNA was more frequently detected in those patients that developed distant metastasis. Moreover, in our preliminary follow-up evaluation, we did not find aberrant methylation in patients without detectable disease and follow-up longer than 1 year. Our limited results suggest that epigenetic alterations may be an important indicator of metastases or recurrence, but larger prospective trials are needed to further establish these observations.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by ROI DE012588-01. M. S-C. and M. E. are recipients of a Spanish Ministerio de Educacion y Cultura Award. J. G. H. and J. J. are Valvano Foundation Scholars.

² Both authors contributed equally to this work.

³ To whom requests for reprints should be addressed, at Department of Otolaryngology–Head and Neck Surgery, Division of Head and Neck Cancer Research, Johns Hopkins University School of Medicine, 818 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21206-2198. E-mail: dsidrans{at}jhmi.edu

⁴ The abbreviations used are: HNSCC, head and neck squamous cell carcinoma; MGMT, O⁶-methylguanine-DNA-methyltransferase; GST, glutathione S-transferase; DAP-kinase, death-associated protein kinase; MI, microsatellite instability; MSP, methylation-specific PCR.

Received 10/ 5/99. Accepted 1/ 4/00.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. Vokes E. E., Weichselbaum R. R., Lippman S. M., Hong W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.[Free Full Text]
2. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.[Medline]
3. Merlo A., Herman J. G., Mo L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.[Medline]
4. Herman J. G., Latif F., Weng W., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S. R., Gnarra J. R., Linehan W. M., Baylin S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinomas. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.[Abstract/Free Full Text]
5. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K. V., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin S. B. Incidence of functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.[Abstract/Free Full Text]
6. Lee W. H., Morton P. A., Epstein J. I., Brooks J. D., Campbell P. A., Bova G. S., Hsiech W. S., Isaacs W. B., Nelson W. G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA, 91: 11733-11737, 1994.[Abstract/Free Full Text]
7. Esteller M., Hamilton S. R., Burger P. C., Baylin S. B., Herman J. G. Inactivation of O⁶-methylguanine-DNA-methyltransferase by promoter hypermethylation is a common event in multiple human neoplasia. Cancer Res., 59: 793-797, 1999.[Abstract/Free Full Text]
8. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S. B., Herman J. G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res., 59: 67-70, 1999.[Abstract/Free Full Text]
9. Leon S. A., Shapiro B., Sklaroff D. M., Yaros M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res., 37: 646-650, 1977.[Abstract/Free Full Text]
10. Kopresi M. S., Benko F. A., Kwee C., Leitzel K. E., Lipton A., Gocke C. D. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br. J. Cancer, 76: 1293-1299, 1997.[Medline]
11. Hibi K., Robinson R., Wu L., Hamilton S. R., Sidransky D., Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res., 58: 1405-1407, 1997.[Abstract/Free Full Text]
12. Mulcahy H. E., Lyautey J., Lederry C., Chen X., Anker P., Alstead E. M., Ballinger A., Farthing M. J. G., Stroun M. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin. Cancer Res., 4: 271-275, 1998.[Abstract/Free Full Text]
13. Silva J. M., Dominguez G., Garcia J. M., Gonzalez R., Villanueva M. J., Navarro F., Provencio M., San Martin S., España P., Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res., 59: 3251-3256, 1999.[Abstract/Free Full Text]
14. Vasioukhin V., Anker P., Maurice P., Lyautey J., Lederry C., Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol., 86: 774-779, 1994.[Medline]
15. Nawroz H., Koch W., Anker P., Stroun M., Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med., 2: 1035-1037, 1996.[Medline]
16. Chen X. Q., Stroun M., Magnenat J. L., Nicod L. P., Kurt A. M., Lyautey J., Lederry C., Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med., 2: 1033-1034, 1996.[Medline]
17. Sanchez-Cespedes M., Monzo M., Rosell R., Pifarre A., Calvo R., Lopez-Cabrerizo M. P., Astudillo J. Chromosome 3p alterations in serum DNA in non-small cell lung cancer patients. Ann. Oncol., 9: 1-4, 1998.[Free Full Text]
18. Goessl C., Heicapell R., Münker R., Anker P., Stroun M., Krause H., Müller M., Miller K. Microsatellite analysis of plasma DNA form patients with clear cell renal carcinoma. Cancer Res., 58: 4728-4732, 1998.[Abstract/Free Full Text]
19. Wong I. H. N., Lo Y. M. D., Zhang J., Liew C. T., Ng M. H. L., Wong N., Lai P. B. S., Lau W. Y., Hjelm N. M., Johnson P. J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res., 59: 71-73, 1999.[Abstract/Free Full Text]
20. Herman J. G., Graff J. R., Myohanen S., Hamilton S. R., Nelkin B. D., Baylin S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.[Abstract/Free Full Text]
21. Esteller M., Corn P. G., Urena J. M., Gabrielson E., Baylin S. B., Herman J. G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res., 58: 4515-4518, 1998.[Abstract/Free Full Text]
22. Katzenellenbogen R. A., Baylin S. B., Herman J. G. Hypermethylation of the DAP-Kinase CpG island is a common alteration in B-cell malignancies. Blood, 93: 4347-4353, 1999.[Abstract/Free Full Text]
23. Reed A. L., Califano J., Cairns P., Westra W. H., Jones R. M., Koch W., Ahrendt S., Eby Y., Sewell D., Nawroz H., Bartek J., Sidransky D. High frequency of p16 (CDKN2/MTS1/INK4) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.[Abstract/Free Full Text]
24. Inbal B., Cohen O., Polak-Charcon S., Kopolovic J., Vadai E., Eisenbach I., Kimchi A. DAP-kinase links the control of apoptosis to metastasis. Nature (Lond.), 390: 180-184, 1997.[Medline]
25. Mao L., Lee D. J., Tockman M. S., Erozan Y. S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. USA, 91: 9871-9875, 1994.[Abstract/Free Full Text]
26. Ahrdent S. A., Chow J. T., Xu L. H., Yang S. C., Eisenberger C. F., Esteller M., Herman J. G., Wu L., Decker A., Jen J., Sidransky D. Molecular detection of tumor cells in bronchioalveolar lavage from patients with early lung cancer. J. Natl. Cancer Inst., 91: 332-339, 1999.[Abstract/Free Full Text]
27. Castells A., Puig P., Mora J., Boadas J., Boix J., Urgell E., Sole M., Capella G., Luis F., Fernandez-Cruz L., Navarro S., Farre A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J. Clin. Oncol., 17: 578-584, 1999.[Abstract/Free Full Text]

This article has been cited by other articles:

				K. W. Ong, M. Teo, V. Lee, D. Ong, A. Lee, C. S. Tan, A. Vathsala, and H. C. Toh Expression of EBV Latent Antigens, Mammalian Target of Rapamycin, and Tumor Suppression Genes in EBV-Positive Smooth Muscle Tumors: Clinical and Therapeutic Implications Clin. Cancer Res., September 1, 2009; 15(17): 5350 - 5358. [Abstract] [Full Text] [PDF]

				D. M.E.I. Hellebrekers, M. H.F.M. Lentjes, S. M. van den Bosch, V. Melotte, K. A.D. Wouters, K. L.J. Daenen, K. M. Smits, Y. Akiyama, Y. Yuasa, S. Sanduleanu, et al. GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3990 - 3997. [Abstract] [Full Text] [PDF]

				E C W Hung, R W K Chiu, and Y M D Lo Detection of circulating fetal nucleic acids: a review of methods and applications J. Clin. Pathol., April 1, 2009; 62(4): 308 - 313. [Abstract] [Full Text] [PDF]

				N. S. Nagaraj Evolving 'omics' technologies for diagnostics of head and neck cancer Brief Funct Genomic Proteomic, March 9, 2009; (2009) elp004v1. [Abstract] [Full Text] [PDF]

				A. Nacci, I. Dallan, L. Bruschini, A. C. Traino, E. Panicucci, P. Bruschini, V. Mancini, F. Rognini, and B. Fattori Plasma Homocysteine, Folate, and Vitamin B12 Levels in Patients With Laryngeal Cancer Arch Otolaryngol Head Neck Surg, December 1, 2008; 134(12): 1328 - 1333. [Abstract] [Full Text] [PDF]

				K. Amara, M. Trimeche, S. Ziadi, A. Laatiri, M. Hachana, and S. Korbi Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas Ann. Onc., October 1, 2008; 19(10): 1774 - 1786. [Abstract] [Full Text] [PDF]

				A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107. [Abstract] [Full Text] [PDF]

				M. S. Kim, K. Yamashita, Y. K. Chae, Y. Tokumaru, X. Chang, M. Zahurak, M. Osada, H. L. Park, A. Chuang, J. A. Califano, et al. A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6658 - 6665. [Abstract] [Full Text] [PDF]

				K. Chen, R. Sawhney, M. Khan, M. S. Benninger, Z. Hou, S. Sethi, J. K. Stephen, and M. J. Worsham Methylation of Multiple Genes as Diagnostic and Therapeutic Markers in Primary Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1131 - 1138. [Abstract] [Full Text] [PDF]

				T. Martone, A. Gillio-Tos, L. De Marco, V. Fiano, M. Maule, A. Cavalot, M. Garzaro, F. Merletti, and G. Cortesina Association Between Hypermethylated Tumor and Paired Surgical Margins in Head and Neck Squamous Cell Carcinomas Clin. Cancer Res., September 1, 2007; 13(17): 5089 - 5094. [Abstract] [Full Text] [PDF]

				J. K. Stephen, L. E. Vaught, K. M. Chen, V. Shah, V. G. Schweitzer, G. Gardner, M. S. Benninger, and M. J. Worsham An Epigenetically Derived Monoclonal Origin for Recurrent Respiratory Papillomatosis Arch Otolaryngol Head Neck Surg, July 1, 2007; 133(7): 684 - 692. [Abstract] [Full Text] [PDF]

				J. Kagan, S. Srivastava, P. E. Barker, S. A. Belinsky, and P. Cairns Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools Cancer Res., May 15, 2007; 67(10): 4545 - 4549. [Abstract] [Full Text] [PDF]

				R. W.K. Chiu, S. S.C. Chim, I. H.N. Wong, C. S.C. Wong, W.-S. Lee, K. F. To, J. H.M. Tong, R. K.C. Yuen, A. S.W. Shum, J. K.C. Chan, et al. Hypermethylation of RASSF1A in Human and Rhesus Placentas Am. J. Pathol., March 1, 2007; 170(3): 941 - 950. [Abstract] [Full Text] [PDF]

				C. A. Righini, F. de Fraipont, J.-F. Timsit, C. Faure, E. Brambilla, E. Reyt, and M.-C. Favrot Tumor-Specific Methylation in Saliva: A Promising Biomarker for Early Detection of Head and Neck Cancer Recurrence Clin. Cancer Res., February 15, 2007; 13(4): 1179 - 1185. [Abstract] [Full Text] [PDF]

				A. K. Pathak, M. Bhutani, S. Kumar, A. Mohan, and R. Guleria Circulating Cell-Free DNA in Plasma/Serum of Lung Cancer Patients as a Potential Screening and Prognostic Tool Clin. Chem., October 1, 2006; 52(10): 1833 - 1842. [Abstract] [Full Text] [PDF]

				N. Umetani, A. E. Giuliano, S. H. Hiramatsu, F. Amersi, T. Nakagawa, S. Martino, and D. S.B. Hoon Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in Serum J. Clin. Oncol., September 10, 2006; 24(26): 4270 - 4276. [Abstract] [Full Text] [PDF]

				R. J. Shaw, E. K. Akufo-Tetteh, J. M. Risk, J. K. Field, and T. Liloglou Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing Nucleic Acids Res., June 28, 2006; 34(11): e78 - e78. [Abstract] [Full Text] [PDF]

				M. J. Worsham, K. M. Chen, V. Meduri, A. O. H. Nygren, A. Errami, J. P. Schouten, and M. S. Benninger Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 668 - 677. [Abstract] [Full Text] [PDF]

				M. S. Kim, K. Yamashita, J. H. Baek, H. L. Park, A. L. Carvalho, M. Osada, M. O. Hoque, S. Upadhyay, M. Mori, C. Moon, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., April 1, 2006; 66(7): 3409 - 3418. [Abstract] [Full Text] [PDF]

				K. Yamashita, H. L. Park, M. S. Kim, M. Osada, Y. Tokumaru, H. Inoue, M. Mori, and D. Sidransky PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Res., April 1, 2006; 66(7): 3921 - 3927. [Abstract] [Full Text] [PDF]

				T. L. Lee, J. Yeh, C. Van Waes, and Z. Chen Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas Mol. Cancer Ther., January 1, 2006; 5(1): 8 - 19. [Abstract] [Full Text] [PDF]

				M. V. Brock, C. M. Hooker, R. Yung, M. Guo, Y. Han, S. E. Ames, D. Chang, S. C. Yang, D. Mason, M. Sussman, et al. Can We Improve the Cytologic Examination of Malignant Pleural Effusions Using Molecular Analysis? Ann. Thorac. Surg., October 1, 2005; 80(4): 1241 - 1247. [Abstract] [Full Text] [PDF]

				M. O. Hoque, O. Topaloglu, S. Begum, R. Henrique, E. Rosenbaum, W. Van Criekinge, W. H. Westra, and D. Sidransky Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects J. Clin. Oncol., September 20, 2005; 23(27): 6569 - 6575. [Abstract] [Full Text] [PDF]

				W.-D. Chen, Z. J. Han, J. Skoletsky, J. Olson, J. Sah, L. Myeroff, P. Platzer, S. Lu, D. Dawson, J. Willis, et al. Detection in Fecal DNA of Colon Cancer-Specific Methylation of the Nonexpressed Vimentin Gene J Natl Cancer Inst, August 3, 2005; 97(15): 1124 - 1132. [Abstract] [Full Text] [PDF]

				M. O. Hoque, E. Rosenbaum, W. H. Westra, M. Xing, P. Ladenson, M. A. Zeiger, D. Sidransky, and C. B. Umbricht Quantitative Assessment of Promoter Methylation Profiles in Thyroid Neoplasms J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4011 - 4018. [Abstract] [Full Text] [PDF]

				K. Miyamoto and T. Ushijima Diagnostic and Therapeutic Applications of Epigenetics Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301. [Abstract] [Full Text] [PDF]

				D. L. Mandelker, K. Yamashita, Y. Tokumaru, K. Mimori, D. L. Howard, Y. Tanaka, A. L. Carvalho, W.-W. Jiang, H. L. Park, M. S. Kim, et al. PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma Cancer Res., June 1, 2005; 65(11): 4963 - 4968. [Abstract] [Full Text] [PDF]

				H. Zou, N. K. Osborn, J. J. Harrington, K. K. Klatt, J. R. Molina, L. J. Burgart, and D. A. Ahlquist Frequent Methylation of Eyes Absent 4 Gene in Barrett's Esophagus and Esophageal Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 830 - 834. [Abstract] [Full Text] [PDF]

				A. L. Russo, A. Thiagalingam, H. Pan, J. Califano, K.-h. Cheng, J. F. Ponte, D. Chinnappan, P. Nemani, D. Sidransky, and S. Thiagalingam Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2466 - 2470. [Abstract] [Full Text] [PDF]

				S. Temam, J. Benard, C. Dugas, M. Trassard, E. Gormally, J.-C. Soria, S. Faivre, B. Luboinski, P. Marandas, P. Hainaut, et al. Molecular Detection of Early-Stage Laryngopharyngeal Squamous Cell Carcinomas Clin. Cancer Res., April 1, 2005; 11(7): 2547 - 2551. [Abstract] [Full Text] [PDF]

				M. Rodriguez-Pinilla, J. L. Rodriguez-Peralto, R. Hitt, J. J. Sanchez, C. Ballestin, A. Diez, L. Sanchez-Verde, F. Alameda, and M. Sanchez-Cespedes Cyclin A as a Predictive Factor for Chemotherapy Response in Advanced Head and Neck Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8486 - 8492. [Abstract] [Full Text] [PDF]

				X. Tang, W. Wu, S.-y. Sun, I. I. Wistuba, W. K. Hong, and L. Mao Hypermethylation of the Death-Associated Protein Kinase Promoter Attenuates the Sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Non-Small Cell Lung Cancer Cells Mol. Cancer Res., December 1, 2004; 2(12): 685 - 691. [Abstract] [Full Text] [PDF]

				P. M. Das and R. Singal DNA Methylation and Cancer J. Clin. Oncol., November 15, 2004; 22(22): 4632 - 4642. [Abstract] [Full Text] [PDF]

				I. I. de Caceres, C. Battagli, M. Esteller, J. G. Herman, E. Dulaimi, M. I. Edelson, C. Bergman, H. Ehya, B. L. Eisenberg, and P. Cairns Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients Cancer Res., September 15, 2004; 64(18): 6476 - 6481. [Abstract] [Full Text] [PDF]

				E. Dulaimi, J. Hillinck, I. I. de Caceres, T. Al-Saleem, and P. Cairns Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients Clin. Cancer Res., September 15, 2004; 10(18): 6189 - 6193. [Abstract] [Full Text] [PDF]

				Y. Tokumaru, K. Yamashita, M. Osada, S. Nomoto, D.-I. Sun, Y. Xiao, M. O. Hoque, W. H. Westra, J. A. Califano, and D. Sidransky Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing Cancer Res., September 1, 2004; 64(17): 5982 - 5987. [Abstract] [Full Text] [PDF]

				M. O. Hoque, S. Begum, O. Topaloglu, C. Jeronimo, E. Mambo, W. H. Westra, J. A. Califano, and D. Sidransky Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer Cancer Res., August 1, 2004; 64(15): 5511 - 5517. [Abstract] [Full Text] [PDF]

				S. G. Soltys, Q.-T. Le, G. Shi, R. Tibshirani, A. J. Giaccia, and A. C. Koong The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers Clin. Cancer Res., July 15, 2004; 10(14): 4806 - 4812. [Abstract] [Full Text] [PDF]

				C. Zuo, L. Ai, P. Ratliff, J. Y. Suen, E. Hanna, T. P. Brent, and C.-Y. Fan O6-Methylguanine-DNA Methyltransferase Gene: Epigenetic Silencing and Prognostic Value in Head and Neck Squamous Cell Carcinoma Cancer Epidemiol. Biomarkers Prev., June 1, 2004; 13(6): 967 - 975. [Abstract] [Full Text] [PDF]

				L. C. Pulling, B. R. Vuillemenot, J. A. Hutt, T. R. Devereux, and S. A. Belinsky Aberrant Promoter Hypermethylation of the Death-Associated Protein Kinase Gene Is Early and Frequent in Murine Lung Tumors Induced by Cigarette Smoke and Tobacco Carcinogens Cancer Res., June 1, 2004; 64(11): 3844 - 3848. [Abstract] [Full Text] [PDF]

				S.-i. Maruya, J.-P. J. Issa, R. S. Weber, D. I. Rosenthal, J. C. Haviland, R. Lotan, and A. K. El-Naggar Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma: Incidence and Potential Implications Clin. Cancer Res., June 1, 2004; 10(11): 3825 - 3830. [Abstract] [Full Text] [PDF]

				N. Reesink-Peters, G. B. A. Wisman, C. Jeronimo, C. Y. Tokumaru, Y. Cohen, S. M. Dong, H. G. Klip, H. J. Buikema, A. J.H. Suurmeijer, H. Hollema, et al. Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study Mol. Cancer Res., May 1, 2004; 2(5): 289 - 295. [Abstract] [Full Text] [PDF]

				E. Dulaimi, R. G. Uzzo, R. E. Greenberg, T. Al-Saleem, and P. Cairns Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel Clin. Cancer Res., March 15, 2004; 10(6): 1887 - 1893. [Abstract] [Full Text] [PDF]

				J. T. Wadsworth, K. D. Somers, L. H. Cazares, G. Malik, B.-L. Adam, B. C. Stack Jr., G. L. Wright Jr., and O. J. Semmes Serum Protein Profiles to Identify Head and Neck Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1625 - 1632. [Abstract] [Full Text] [PDF]

				A. Widschwendter, H. M. Muller, H. Fiegl, L. Ivarsson, A. Wiedemair, E. Muller-Holzner, G. Goebel, C. Marth, and M. Widschwendter DNA Methylation in Serum and Tumors of Cervical Cancer Patients Clin. Cancer Res., January 15, 2004; 10(2): 565 - 571. [Abstract] [Full Text] [PDF]

				Genetic and Epigenetic Alterations in Cancer Detection: DAVID SIDRANSKY, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196 Toxicol Pathol, January 1, 2004; 32(1): 138 - 139. [PDF]

				D. Goldenberg, S. Harden, B. G. Masayesva, P. Ha, N. Benoit, W. H. Westra, W. M. Koch, D. Sidransky, and J. A. Califano Intraoperative Molecular Margin Analysis in Head and Neck Cancer Arch Otolaryngol Head Neck Surg, January 1, 2004; 130(1): 39 - 44. [Abstract] [Full Text] [PDF]

				J. T. Wadsworth, K. D. Somers, B. C. Stack Jr, L. Cazares, G. Malik, B.-L. Adam, G. L. Wright Jr, and O. J. Semmes Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles Arch Otolaryngol Head Neck Surg, January 1, 2004; 130(1): 98 - 104. [Abstract] [Full Text] [PDF]

				C. Battagli, R. G. Uzzo, E. Dulaimi, I. Ibanez de Caceres, R. Krassenstein, T. Al-Saleem, R. E. Greenberg, and P. Cairns Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Kidney Cancer Patients Cancer Res., December 15, 2003; 63(24): 8695 - 8699. [Abstract] [Full Text] [PDF]

				Y. Liu, Q. An, L. Li, D. Zhang, J. Huang, X. Feng, S. Cheng, and Y. Gao Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications Carcinogenesis, December 1, 2003; 24(12): 1897 - 1901. [Abstract] [Full Text] [PDF]

				J. G. Herman and S. B. Baylin Gene Silencing in Cancer in Association with Promoter Hypermethylation N. Engl. J. Med., November 20, 2003; 349(21): 2042 - 2054. [Full Text] [PDF]

				H. M. Muller, A. Widschwendter, H. Fiegl, L. Ivarsson, G. Goebel, E. Perkmann, C. Marth, and M. Widschwendter DNA Methylation in Serum of Breast Cancer Patients: An Independent Prognostic Marker Cancer Res., November 15, 2003; 63(22): 7641 - 7645. [Abstract] [Full Text] [PDF]

				A. N. Reddy, W. W. Jiang, M. Kim, N. Benoit, R. Taylor, J. Clinger, D. Sidransky, and J. A. Califano Death-Associated Protein Kinase Promoter Hypermethylation in Normal Human Lymphocytes Cancer Res., November 15, 2003; 63(22): 7694 - 7698. [Abstract] [Full Text] [PDF]

				Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]

				S. M. Dong, D.-I. Sun, N. E. Benoit, I. Kuzmin, M. I. Lerman, and D. Sidransky Epigenetic Inactivation of RASSF1A in Head and Neck Cancer Clin. Cancer Res., September 1, 2003; 9(10): 3635 - 3640. [Abstract] [Full Text] [PDF]

				C. Jeronimo, I. Costa, M. C. Martins, P. Monteiro, S. Lisboa, C. Palmeira, R. Henrique, M. R. Teixeira, and C. Lopes Detection of Gene Promoter Hypermethylation in Fine Needle Washings from Breast Lesions Clin. Cancer Res., August 1, 2003; 9(9): 3413 - 3417. [Abstract] [Full Text] [PDF]

				C. Balana, J. L. Ramirez, M. Taron, Y. Roussos, A. Ariza, R. Ballester, C. Sarries, P. Mendez, J. J. Sanchez, and R. Rosell O6-methyl-guanine-DNA methyltransferase Methylation in Serum and Tumor DNA Predicts Response to 1,3-Bis(2-Chloroethyl)-1-Nitrosourea but not to Temozolamide Plus Cisplatin in Glioblastoma Multiforme Clin. Cancer Res., April 1, 2003; 9(4): 1461 - 1468. [Abstract] [Full Text] [PDF]

				H. W. Chang, A. Chan, D. L. W. Kwong, W. I. Wei, J. S. T. Sham, and A. P. W. Yuen Detection of Hypermethylated RIZ1 Gene in Primary Tumor, Mouth, and Throat Rinsing Fluid, Nasopharyngeal Swab, and Peripheral Blood of Nasopharyngeal Carcinoma Patient Clin. Cancer Res., March 1, 2003; 9(3): 1033 - 1038. [Abstract] [Full Text] [PDF]

				C Jeronimo, R Henrique, P F Campos, J Oliveira, O L Caballero, C Lopes, and D Sidransky Endothelin B receptor gene hypermethylation in prostate adenocarcinoma J. Clin. Pathol., January 1, 2003; 56(1): 52 - 55. [Abstract] [Full Text] [PDF]

				D J Smiraglia, L T Smith, J C Lang, L J Rush, Z Dai, D E Schuller, and C Plass Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC) J. Med. Genet., January 1, 2003; 40(1): 25 - 33. [Abstract] [Full Text] [PDF]

				M. P. Rosin, W. L. Lam, C. Poh, N. D. Le, R. J. Li, T. Zeng, R. Priddy, and L. Zhang 3p14 and 9p21 Loss Is a Simple Tool for Predicting Second Oral Malignancy at Previously Treated Oral Cancer Sites Cancer Res., November 15, 2002; 62(22): 6447 - 6450. [Abstract] [Full Text] [PDF]

				K. Ogi, M. Toyota, M. Ohe-Toyota, N. Tanaka, M. Noguchi, T. Sonoda, G. Kohama, and T. Tokino Aberrant Methylation of Multiple Genes and Clinicopathological Features in Oral Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2002; 8(10): 3164 - 3171. [Abstract] [Full Text] [PDF]

				J. H. M. Tong, R. K. Y. Tsang, K.-W. Lo, J. K. S. Woo, J. Kwong, M. W. Y. Chan, A. R. Chang, C. A. van Hasselt, D. P. Huang, and K.-F. To Quantitative Epstein-Barr Virus DNA Analysis and Detection of Gene Promoter Hypermethylation in Nasopharyngeal (NP) Brushing Samples from Patients with NP Carcinoma Clin. Cancer Res., August 1, 2002; 8(8): 2612 - 2619. [Abstract] [Full Text] [PDF]

				T.-L. Lee, W. K. Leung, M. W. Y. Chan, E. K. W. Ng, J. H. M. Tong, K.-W. Lo, S. C. S. Chung, J. J. Y. Sung, and K.-F. To Detection of Gene Promoter Hypermethylation in the Tumor and Serum of Patients with Gastric Carcinoma Clin. Cancer Res., June 1, 2002; 8(6): 1761 - 1766. [Abstract] [Full Text] [PDF]

				R. K. C. Ngan, T. T. C. Yip, W.-W. Cheng, J. K. C. Chan, W. C. S. Cho, V. W. S. Ma, K.-K. Wan, S.-K. Au, C.-K. Law, and W.-H. Lau Circulating Epstein-Barr Virus DNA in Serum of Patients with Lymphoepithelioma-like Carcinoma of the Lung: A Potential Surrogate Marker for Monitoring Disease Clin. Cancer Res., April 1, 2002; 8(4): 986 - 994. [Abstract] [Full Text] [PDF]

				M. W. Y. Chan, L. W. Chan, N. L. S. Tang, J. H. M. Tong, K. W. Lo, T. L. Lee, H. Y. Cheung, W. S. Wong, P. S. F. Chan, F. M. M. Lai, et al. Hypermethylation of Multiple Genes in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients Clin. Cancer Res., February 1, 2002; 8(2): 464 - 470. [Abstract] [Full Text] [PDF]

				S. M. Dong, S. I. Pai, S.-H. Rha, A. Hildesheim, R. J. Kurman, P. E. Schwartz, R. Mortel, L. McGowan, M. D. Greenberg, W. A. Barnes, et al. Detection and Quantitation of Human Papillomavirus DNA in the Plasma of Patients with Cervical Carcinoma Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 3 - 6. [Abstract] [Full Text]

				R. Todd, P.W. Hinds, K. Munger, A.K. Rustgi, O.G. Opitz, Y. Suliman, and D.T. Wong CELL CYCLE DYSREGULATION IN ORAL CANCER Critical Reviews in Oral Biology & Medicine, January 1, 2002; 13(1): 51 - 61. [Abstract] [Full Text] [PDF]

				J. Kwong, K.-W. Lo, K.-F. To, P. M. L. Teo, P. J. Johnson, and D. P. Huang Promoter Hypermethylation of Multiple Genes in Nasopharyngeal Carcinoma Clin. Cancer Res., January 1, 2002; 8(1): 131 - 137. [Abstract] [Full Text] [PDF]

				H.-Z. Zou, B.-M. Yu, Z.-W. Wang, J.-Y. Sun, H. Cang, F. Gao, D. H. Li, R. Zhao, G.-G. Feng, and J. Yi Detection of Aberrant p16 Methylation in the Serum of Colorectal Cancer Patients Clin. Cancer Res., January 1, 2002; 8(1): 188 - 191. [Abstract] [Full Text] [PDF]

				A. Forastiere, W. Koch, A. Trotti, and D. Sidransky Head and Neck Cancer N. Engl. J. Med., December 27, 2001; 345(26): 1890 - 1900. [Full Text] [PDF]

				G. Shohat, T. Spivak-Kroizman, O. Cohen, S. Bialik, G. Shani, H. Berrisi, M. Eisenstein, and A. Kimchi The Pro-apoptotic Function of Death-associated Protein Kinase Is Controlled by a Unique Inhibitory Autophosphorylation-based Mechanism J. Biol. Chem., December 7, 2001; 276(50): 47460 - 47467. [Abstract] [Full Text] [PDF]

				A. V. Velentza, A. M. Schumacher, C. Weiss, M. Egli, and D. M. Watterson A Protein Kinase Associated with Apoptosis and Tumor Suppression. STRUCTURE, ACTIVITY, AND DISCOVERY OF PEPTIDE SUBSTRATES J. Biol. Chem., October 12, 2001; 276(42): 38956 - 38965. [Abstract] [Full Text] [PDF]

				K. Hibi, M. Taguchi, H. Nakayama, T. Takase, Y. Kasai, K. Ito, S. Akiyama, and A. Nakao Molecular Detection of p16 Promoter Methylation in the Serum of Patients with Esophageal Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2001; 7(10): 3135 - 3138. [Abstract] [Full Text] [PDF]

				P. Cairns, M. Esteller, J. G. Herman, M. Schoenberg, C. Jeronimo, M. Sanchez-Cespedes, N.-H. Chow, M. Grasso, L. Wu, W. B. Westra, et al. Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation Clin. Cancer Res., September 1, 2001; 7(9): 2727 - 2730. [Abstract] [Full Text] [PDF]

				S. M. Dong, H.-S. Kim, S.-H. Rha, and D. Sidransky Promoter Hypermethylation of Multiple Genes in Carcinoma of the Uterine Cervix Clin. Cancer Res., July 1, 2001; 7(7): 1982 - 1986. [Abstract] [Full Text] [PDF]

				G. Sozzi, D. Conte, L. Mariani, S. Lo Vullo, L. Roz, C. Lombardo, M. A. Pierotti, and L. Tavecchio Analysis of Circulating Tumor DNA in Plasma at Diagnosis and during Follow-Up of Lung Cancer Patients Cancer Res., June 1, 2001; 61(12): 4675 - 4678. [Abstract] [Full Text] [PDF]

				S. B. Baylin, M. Esteller, M. R. Rountree, K. E. Bachman, K. Schuebel, and J. G. Herman Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer Hum. Mol. Genet., April 1, 2001; 10(7): 687 - 692. [Abstract] [Full Text] [PDF]

				M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman A Gene Hypermethylation Profile of Human Cancer Cancer Res., April 1, 2001; 61(8): 3225 - 3229. [Abstract] [Full Text]

				M. F. Spafford, W. M. Koch, A. L. Reed, J. A. Califano, L. H. Xu, C. F. Eisenberger, L. Yip, P. L. Leong, L. Wu, S. X. Liu, et al. Detection of Head and Neck Squamous Cell Carcinoma among Exfoliated Oral Mucosal Cells by Microsatellite Analysis Clin. Cancer Res., March 1, 2001; 7(3): 607 - 612. [Abstract] [Full Text]

				W. M. Grady, A. Rajput, J. D. Lutterbaugh, and S. D. Markowitz Detection of Aberrantly Methylated hMLH1 Promoter DNA in the Serum of Patients with Microsatellite Unstable Colon Cancer Cancer Res., February 1, 2001; 61(3): 900 - 902. [Abstract] [Full Text]

				S. L. B. Rosas, W. Koch, M. d. G. d. C. Carvalho, L. Wu, J. Califano, W. Westra, J. Jen, and D. Sidransky Promoter Hypermethylation Patterns of p16, O6-Methylguanine-DNA-methyltransferase, and Death-associated Protein Kinase in Tumors and Saliva of Head and Neck Cancer Patients Cancer Res., February 1, 2001; 61(3): 939 - 942. [Abstract] [Full Text]

				S. Jahr, H. Hentze, S. Englisch, D. Hardt, F. O. Fackelmayer, R.-D. Hesch, and R. Knippers DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells Cancer Res., February 1, 2001; 61(4): 1659 - 1665. [Abstract] [Full Text]

				S. B. Baylin, S. A. Belinsky, and J. G. Herman Aberrant Methylation of Gene Promoters in Cancer--Concepts, Misconcepts, and Promise J Natl Cancer Inst, September 20, 2000; 92(18): 1460 - 1461. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanchez-Cespedes, M. Articles by Sidransky, D. Search for Related Content PubMed PubMed Citation Articles by Sanchez-Cespedes, M. Articles by Sidransky, D.